调强放疗模式下局部晚期鼻咽癌诱导化疗后同期化疗与单纯放疗疗效比较

目的:探讨调强放疗模式下局部晚期鼻咽癌诱导化疗后同期化疗与单纯放疗临床疗效的比较。方法:回顾性分析2010年-2012年期间在本院采用调强放疗技术治疗的局部晚期鼻咽癌,分期为Ⅲ-Ⅳ期的鼻咽癌患者共120例。所有患者都进行过诱导化疗。放疗范围及剂量为鼻咽原发灶、阳性淋巴结的大体肿瘤体积处方剂量为T1、T2期69.96Gy,T3、T4期72~74Gy;亚临床高危区靶体积处方剂量为60~64Gy;淋巴结阴性引流区处方剂量为50~54Gy。分为单纯放疗组60例,同期化疗组60例。同期化疗方案为单药顺铂为基础的方案。主要观察两组的近期疗效、3年无瘤生存率(DFS)、3年无局部区域复发生存率（LRFS）、3年无远处转移生存率（MFS）、3年总生存率（OS）及治疗的毒副反应情况。结果:两组性别、年龄、病理类型及临床分期的构成比均有可比性。两组患者中位随访36个月。治疗结束3个月两组患者的完全缓解率分别为83.3％、80.0％,3年无瘤生存率分别为78.3％、75.0％,3年的无局部区域复发生存率分别为93.3％、90.0％,3年无远处转移生存分别为81.7％、83.3％,3年总生存率分别为88.3％、86.7％,两组统计学无明显差异。同期化疗组急性毒副反应高于单纯放疗组。结论:在调强放疗治疗模式下,局部晚期鼻咽癌同期化疗与单纯放疗相比,患者的3年总生存率及无瘤生存率未能进一步提高,而急性毒副反应增加,同期化疗在调强放疗模式下治疗策略需要行进一步的临床研究。     

复发性鼻咽癌三维适形放射治疗的疗效分析

目的 分析复发性鼻咽癌三维适形放射治疗的疗效及影响疗效的因素.方法 56例复发性鼻咽癌接受三维适形放射治疗,鼻咽部剂量50～70Gy/36～52d(中位64Gy/44d).结果 全组病例随访3年以上.3年总生存率、无瘤生存率和鼻咽部局部控制率分别为48.2 %、44.6%和53.6%.复发间隔时间＞2年和复发临床分期T2期者,3年生存率和局部控制率高(P＜0.05);再程放疗剂量≥60Gy者,3年生存率和局部控制率优于＜60Gy.结论 三维适形放射治疗是复发性鼻咽癌有效的治疗手段,其复发间隔时间、复发临床分期和再程放疗剂量是影响预后的因素.     

鼻腔副鼻窦恶性肿瘤术后放疗临床分析

目的 探讨影响鼻腔副鼻窦恶性肿瘤术后放疗效果与预后的因素.方法 95例鼻腔副鼻窦恶性肿瘤接受术后放疗,生存率计算采用Kaplan-Meier法,生存率差异检验采用Logrank法,多因素分析采用Cox模型.结果 1,3,5,10年总生存率分别为84.2%、50.5%、44.2%和20.0%.单因素分析显示,性别、年龄、手术方法和肿瘤剂量与生存率无相关性;而临床分期、病理类型与生存率相关.多因素分析显示,临床分期、病理类型是影响预后的独立因素.视力障碍、听力障碍、口干是治疗的主要毒副作用.结论 临床分期、病理类型是影响鼻腔副鼻窦恶性肿瘤术后放疗效果和预后的重要因素,术后放疗能够提高鼻腔副鼻窦恶性肿瘤的疗效.     

53例膀胱癌放射治疗的临床分析

目的总结膀胱癌放射治疗的疗效和毒副反应,评价和分析影响因素.方法对53例病理诊断为膀胱癌的患者进行回顾性分析,其中T2期22例,T3期10例,T4期21例.9例有淋巴结转移;5例有远处转移.病理分类为:移形细胞癌40例,腺癌7例,鳞癌3例,移形细胞癌伴鳞癌3例.所有病人均接受了放射治疗,采用常规分割,照射剂量最低24.01 Gy,最高69.94 Gy,中位52.25 Gy.局控及生存分析用Kaplan-Meier法及Logrank检验.多因素分析采用Cox回归模型.结果中位随访期24个月,1、2、5年生存率分别为75.6%,51.1%和27.2%,1、2、5年局部失败率分别为14.8%,40.6%和56.2%.35例死亡,其中31例死于肿瘤,单因素分析显示只有不同分期的生存率有显著性差异,无肿瘤复发行放疗者较复发后放疗者局部失败低.多因素分析也表明T分期(T2期或T3+T4期)、N分期对于患者生存和局部控制均有统计学意义.结论对预后影响的关键是肿瘤的临床分期.全膀胱根治切除术后复发的治疗,如何提高局部控制是关键因素.需要随机研究来进一步探讨放射治疗在膀胱癌综合治疗的作用和地位.     

局部晚期直肠癌术前调强放疗同步化疗的疗效评价及预后因素分析

目的:观察并分析术前调强放疗同步化疗治疗局部晚期直肠癌的病理降期情况、临床疗效和预后因素.方法:回顾性分析2010年1月1日至2013年7月31日间接受术前同步放化疗随后行根治性手术的60例初治Ⅱ、Ⅲ期直肠癌患者的临床资料.全部患者接受调强放射治疗,总剂量为50Gy/25次,同期行氟尿嘧啶为基础的化疗,放化疗结束后间隔4~8周行手术治疗.结果:肿瘤病理退缩分级(tumor regression grading,TRG)0级为8例、1级为 12例、2级 为11例、3级为 20例、4级即病理完全缓解(complete responce rate,pCR)为9例,pCR率为15%,病理有效率为86.7%,T分期降期55%,N分期降期51.9%.手术并发症发生率为25.0%.3年总生存率(OS)为88.3%,3年无瘤生存率(DFS)为85.5%,3年局部复发率(LRR)为11.6%,3年远处转移率(DMR)为13.3%,3年无局部复发生存率(LRFS)为88.3%,3年无远处转移生存率(DRFS)为 86.7%.Kaplan-Meier分析及COX回归分析均表明TRG分级对患者总生存期的影响具有统计学意义.结论:局部晚期直肠癌术前调强放疗同期化疗能使肿瘤降期,提高手术切除率和生存率,3年局部控制好.pCR 和接近pCR 患者有更好的生存期.     

局部晚期直肠癌术前同步放化疗临床意义的初步探讨

目的:评价术前FOLFOX4方案同步放射治疗局部晚期直肠癌的临床疗效和不良反应。方法:回顾性分析38例局部晚期直肠癌患者(cTNMⅡ期和Ⅲ期)的临床资料,患者均接受FOLFOX4方案(奥沙利铂+亚叶酸钙+5-氟尿嘧啶)化疗同步三维适形放疗,放疗采用6/15MV X射线对肿瘤局部照射,1.8～2.0Gy/次,总剂量45～50.4Gy。放疗结束后4～6周接受手术治疗。结果:新辅助放化疗的不良反应较小,主要是白细胞下降、手足麻木、恶心、呕吐及放射性直肠炎,全部患者均完成了治疗,其中31例(82%)施行了保肛手术,7例施行了Miles手术。术前肿瘤分期明显降低,新辅助治疗后原诊断为T3期的30例患者中5例降为T1期,11例降为T2期,其侵犯淋巴结均有缩小,其中10例转阴。原诊断为T4期的8例患者中1例降为T1期,2例降为T2期,3例降为T3期,其侵犯淋巴结也均有不同程度缩小,其中4例转阴。手术后病理判断CR 5例(13%),局部区域淋巴结阴性27例(71%)。结论:术前三维适形放疗同步FOL-FOX4方案化疗治疗局部晚期进展期直肠癌,能降低肿瘤临床分期,提高根治性切除率和保肛成功率,毒副作用小,是局部晚期直肠癌综合治疗的一种有效方法。     

早期鼻腔和韦氏环NK/T细胞淋巴瘤调强放疗的初步结果

目的 回顾性分析早期鼻腔和韦氏环NK/T细胞淋巴瘤调强放疗(IMRT)的初步临床结果.方法 48例患者中42例为原发鼻腔NK/T细胞淋巴瘤,6例为韦氏环NK/T细胞淋巴瘤.根据Ann Arbor分期,I_E期37例,Ⅱ_E期11例.22例接受单纯放疗,26例接受放化疗.95%计划靶体积(PTV)处方剂量为50 Gy.放疗副反应分级采用RTOG标准.局部控制率和生存率用Kaplan-Meier法计算.结果 中佗随访18个月,2年局部控制率、无进展生存率和总生存率分别为100%、73%和75%.剂量体积直方图显示PTV最高、平均、最低剂量均值分别为62.6、55.0、20.3 Gy,接受低于95%处方剂量的体积仅占靶体积的2.4%.脑干、脊髓、视交叉、左视神经、右视神经、左晶体和右晶体接受的最高剂量均值分别为43.5、32.7、48.2、50.3、51.3、7.8和7.6 Gy.左腮腺、右腮腺、垂体、左颞颌关节和右颞颌关节接受的平均剂量分别为17.1、16.5、32.5、47.3和46.8 Gy.全组口腔黏膜反应1级37%、2级41%、3级16%;皮肤急性反应1级78%、2级16%;急性口干反应1级65%、2级18%.结论 鼻腔和韦氏环NK/T细胞淋巴瘤IMRT使靶区剂量分布均匀,有效保护了腮腺和其他重要器官,并取得了很好的局部控制率和总生存率.     

鼻咽癌调强放疗对腮腺功能的影响

目的 评价调强放疗对鼻咽癌患者腮腺功能的影响.方法 搜集2003年前2年内83例初治患者放疗前、放疗结束时、放疗后6个月和1、2、3、4、5年的口干变化情况的资料,通过分析其与腮腺受照剂量关系来评价调强放疗对腮腺功能影响.结果 共入组83例,其中Ⅰ期4例,Ⅱ期31例,Ⅲ期31例,ⅣA期17例;16例接受放化综合治疗.中位随访时间65个月,5年局部和区域控制率为96%和95%,总生存率为80%.放疗后7个时间段轻和中度口干发生率分别为42%、51%、71%、77%、58%、38%、26%和52%、53%、21%、8%、3%、2%、2%,无重度口干.双侧腮腺受照射平均剂量为34.34 Gy.放疗后6个月口干分级与腮腺平均受照剂量呈正相关,双侧腮腺50%体积受照剂量是放疗后6个月时口干分级的独立影响因素.当腮腺平均剂量≤33 Gy和D50≤29 Gy时,腮腺功能可得到较好地保护.结论 调强放疗在提高鼻咽癌局部和区域控制率的同时,降低了腮腺的受照剂量,减少了腮腺功能的损伤.     

老年食管癌患者三维适形或调强放疗疗效及预后

目的:分析70岁以上老年食管癌患者对单纯三维适形放射治疗(3DCRT)或调强放射治疗(IMRT)技术的耐受性和近远期疗效.方法: 回顾分析53例未手术仅单纯放疗的食管癌患者,年龄70-94岁,中位74岁,46例患者合并内科疾病.临床分期T1-4,均无远处转移.采用三维适形放射治疗(3DCRT)和调强放射治疗(IMRT)技术,靶区剂量范围26.1-72.9Gy,单次剂量1.8-2.2Gy.95%的计划靶区满足处方剂量.生存率采用Kaplan-Meier,组间生存率比较采用Log rank检验,组间率的比较采用χ2检验.结果:88.7%的患者完成治疗剂量,88.2% 完全缓解(CR),2年总生存率(OS)、癌症相关生存率(CSS)分别为 37.4%和48.2%.与CR相关因素包括有无内科合并症、疗前血红蛋白(Hb)、肿瘤体积(GTV)、ECOG评分、T分期、有无淋巴结转移和放疗剂量.单因素分析与OS和CSS均相关的因素包括疗前Hb、ECOG评分和近期疗效,而内科合并症、GTV体积与OS相关,内科合并症中仅有无慢阻肺与CSS相关.多因素分析与二者相关的仅疗前Hb、近期疗效.结论:因内科疾病不能手术老年患者,单纯3DCRT或IMRT放疗耐受性好,近远期疗效好.影响总生存率的独立预后因素主要是完全缓解率和疗前Hb.     

38例鼻腔鼻窦肉瘤治疗回顾

对我院收治的38例鼻腔、鼻窦肉瘤作出回顾性分析,且对其据HE染色的病理切片做出肿瘤的分类和检测,及据1997年UICCGTNM软组织肉瘤进行病理分级.治疗方法为选用6MV的X线+电子束两种混合射线DT65～80Gy放射,术前50～60Gy+鼻腔、鼻窦广泛切除术,鼻腔、鼻窦广泛切除+50～70Gy放疗术3种方法.其结果显示单纯放疗3年生存率为33.3%,5年生存率为0;放疗+手术3年生存率为40%,5年生存率为33.3%;手术+放疗3年生存率为82.6%,5年生存率为58%,由此见手术+放疗对提高病人5年生存率具有积极作用,且软组织肉瘤以高剂量为宜,易采用多次.肿瘤防治杂志,2001,8(特)247-248     

Stage III-IV sinonasal and nasal cavity carcinoma treated with three-dimensional conformal radiotherapy

AIMS AND BACKGROUND: To report the dosimetric data and clinical outcomes of patients with advanced neoplasm of the paranasal sinuses and nasal cavity, treated by three-dimensional conformal radiotherapy. METHODS: Between 2000 and 2005, 31 consecutive patients were treated for locally advanced tumors of paranasal sinuses and nasal cavity. The primary tumor was located as follows: maxillary sinus 15 (48.4%); ethmoid sinus 10 (32.3%); nasal cavity 6 (19.3%). The patients were separated in two groups according to the modality of treatment: group A included 21 patients treated with postoperative three-dimensional conformal radiotherapy with or without chemotherapy; group B included 10 patients treated with radical three-dimensional conformal radiotherapy with or without chemotherapy. The median radiation dose to the planning target volume was 60 Gy (range, 56-63) for patients who underwent complete surgical resection and 68 Gy (range, 64-70) for those who did not have tumor resection or patients with residual disease. RESULTS: The median follow-up was 42 months. Five-year local tumor control and overall survival actuarial rates were 74% and 72%, respectively, in the postoperative setting, 20% and 25%, respectively, with the primary radiotherapy. Local recurrence was the most common site of failure. No patient developed radio-induced blindness; 4 patients underwent enucleation as part of radical surgery. Dosimetric data are reported. CONCLUSIONS: The local control rate for these tumors remains low. The prognosis depends on localization, tumor stage and treatment modality. Three-dimensional conformal radiotherapy reduces the risk on optical pathways but does not modify outcome.     

Paranasal sinuses and nasal cavity cancer: different radiotherapeutic options, results and late damages

From 1970 to 1983, 69 patients, affected by malignant epithelial tumors of paranasal cavities and nasal fossae, were treated with radiotherapy at the Radiology Institute of the University and Radiotherapy Hospital Department of Florence. Primary carcinoma of the maxillary sinus occurred in 44 patients, of the nasal cavity in 20, and of the other sinuses in 5. Most of the patients had locally advanced lesions (63 T3-4: 91.5%) according to the adopted TNM system (Lederman-Gadeberg, Sisson-Jesse). Crude survival data showed 35% and 13% of NED patients at 2 and 5 years, respectively. Local progression was the most important cause of death; patients relapsed within 2 years. The actuarial 5-year survival, corrected for causes of death other than disease, was 32% for the overall series, 32% for maxillary sinus, and 41% for the nasal cavity. There was no difference in survival in patients treated with conventional fractionation (CF) vs. multiple daily fractionation (MDF) -30% vs. 33% at 5 years. The late damages of the radiation therapy in 22 patients without local disease, with a minimum follow-up of 2 years, is also analyzed.     

Nasal and paranasal sinus carcinoma: are we making progress? A series of 220 patients and a systematic review.

BACKGROUND: The authors reviewed treatment results in patients with nasal and paranasal sinus carcinoma from a large retrospective cohort and conducted a systematic literature review. METHODS: Two hundred twenty patients who were treated between 1975 and 1994 with a minimum follow-up of 4 years were reviewed retrospectively. A systematic review of published articles on patients with malignancies of the nasal and paranasal sinuses during the preceding 40 years was performed. RESULTS: The 5-year survival rate was 40%, and the local control rate was 59%. The 5-year actuarial survival rate was 63%, and the local control rate was 57%. Factors that were associated statistically with a worse prognosis, with results expressed as 5-year actuarial specific survival rates, included the following: 1) histology, with rates of 79% for patients with glandular carcinoma, 78% for patients with adenocarcinoma, 60% for patients with squamous cell carcinoma, and 40% for patients with undifferentiated carcinoma; 2) T classification, with rates of 91%, 64%, 72%, and 49% for patients with T1, T2, T3, and T4 tumors, respectively; 3) localization, with rates of 77% for patients with tumors of the nasal cavity, 62% for patients with tumors of the maxillary sinus, and 48% for patients with tumors of the ethmoid sinus; 4) treatment, with rates of 79% for patients who underwent surgery alone, 66% for patients who were treated with a combination of surgery and radiation, and 57% for patients who were treated exclusively with radiotherapy. Local extension factors that were associated with a worse prognosis included extension to the pterygomaxillary fossa, extension to the frontal and sphenoid sinuses, the erosion of the cribriform plate, and invasion of the dura. In the presence of an intraorbital invasion, enucleation was associated with better survival. In multivariate analysis, tumor histology, extension to the pterygomaxillary fossa, and invasion of the dura remained significant. Systematic review data demonstrated a progressive improvement of results for patients with squamous cell and glandular carcinoma, maxillary and ethmoid sinus primary tumors, and most treatment modalities. CONCLUSIONS: Progress in outcome for patients with nasal and paranasal carcinoma has been made during the last 40 years. These data may be used to make baseline comparisons for evaluating newer treatment strategies.     

104例鼻腔鼻窦腺样囊性癌临床分析

背景与目的：腺样囊性癌是一种来自于涎腺组织的少见肿瘤,占所有头颈部恶性肿瘤的1%~2%。鼻腔鼻窦腺样囊性癌的发病率较低,且生长缓慢,较少淋巴转移,但是容易侵犯临近组织和沿着神经浸润生长,后期有较高的复发率和远处转移率,往往预后不佳。该研究总结鼻腔鼻窦腺样囊性癌的临床及病理特点,并对其预后和影响因素进行分析。方法：该研究为一项单中心、回顾性的研究,分析了104例2000年9月—2012年11月间在复旦大学附属眼耳鼻喉科医院接受过放疗的鼻腔鼻窦腺样囊性癌患者,中位随访时间5.1年。使用Kaplan-Meier、log-rank检验和COX比例风险模型进行生存相关的数据分析。结果：患者平均年龄(54.5±11.5)岁,男女各占50%。鼻腔为最常见的原发部位(63.5%),其次为上颌窦(29.8%),临床分期以Ⅲ~Ⅳ期为主(76.0%),手术切缘阳性者为56.7%,出现神经浸润者为34.6%。术后放疗的患者占67.3%,术前放疗占27.9%,仅4.8%的患者采用了单纯放疗,其中29.8%的患者在手术和放疗基础上联合了化疗。采用CRT放疗者为81.7%,采用IMRT放疗者为18.3%。最终18例出现复发,28例出现远处转移,肺部为最常见的转移部位,神经浸润是影响复发或转移的独立危险因素(P=0.0002)。患者的5年和10年总生存率(overall survival,OS)分别为77.0%(95%CI：68.7%~85.3%)和67.8%(95%CI：57.8%~77.9%);5年和10年的无瘤生存率(disease-free survival, DFS)分别为57.8%(95%CI：48.0%~67.7%)和56.4%(95%CI：46.3%~66.4%)。复发或远处转移是显著影响OS的危险因素(未校正HR=60.1,95%CI：8.15~443.1,P<0.0001),神经浸润阳性是显著影响DFS的危险因素(未校正HR=2.99,95%CI：1.642~5.445,P=0.0002)。原发部位、临床分期、手术切缘是否阳性及放疗方式对预后无明显影响。结论：神经浸润、复发或远处转移可能是影响鼻腔鼻窦腺样囊性癌预后的重要因素。     

局部晚期鼻腔鼻窦胚胎性横纹肌肉瘤的多模式治疗经验

目的　探讨无法手术的原发性局部晚期鼻腔鼻窦胚胎性横纹肌肉瘤的多模式综合治疗。方法　对１例无法手术的局部晚期鼻腔鼻窦胚胎性横纹肌肉瘤初治患者,采用术前同步放化疗→手术→术后同步放化疗→辅助化疗的多模式综合治疗,观察治疗效果、不良反应和生活质量情况。结果　经多模式综合治疗后患者的症状、体征完全消失,局部肿瘤病灶接近完全缓解,不良反应可耐受,患者容貌恢复正常。随访至２０１１年３月,患者仍无病生存中,生活质量佳,可正常工作。结论　无法手术的局部晚期鼻腔鼻窦胚胎性横纹肌肉瘤通过多模式综合治疗近期疗效好,症状显著缓解,生活质量提高,生存期延长。     

Cancer of the Nasal Cavity and Paranasal Sinuses: A Clinico-pathological Study of 277 Patients

In the period 1963-1991, a total of 277 consecutive patients with malignant tumours of the nasal cavity and paranasal sinuses were treated at Aarhus University Hospital. The major histological types included squamous cell carcinoma (46%), lymphoma (14%), adenocarcinoma (13%), and malignant melanoma (9%). Kaplan-Meier estimates of 5-year corrected survival (death from cancer) showed the best prognosis for adenoid cystic carcinoma (87%), adenocarcinoma (65%) and lymphoma (56%), and the poorest prognosis for undifferentiated carcinoma (17%) and malignant melanoma (24%). The 5-year corrected survival for squamous cell carcinoma was 35%. Of the 180 patients with treatment failure, the vast majority occurred locally (n = 166); a minor proportion was regional (n = 23) or distant (n = 30). For the 195 patients with carcinoma, the following parameters were of statistical prognostic significance (5-year corrected survival): histological differentiation (moderate-well 65% vs. poor 22%), primary T-site (nasal cavity 56% vs. maxillary antrum 39% vs. other sinuses 24%), tumour stage (T2 68% vs. T3 37% vs. T4 29%), nodal stage (NO 48% vs. Nl-3 21%), treatment (radiotherapy + surgery 56% vs. radiation alone 35%).     

原发鼻腔鼻窦黏膜恶性黑色素瘤94例临床分析

目的 探讨鼻腔鼻窦黏膜恶性黑色素瘤的进展规律及疗效。方法 回顾分析2000—2012年间94例鼻腔鼻窦黑色素瘤资料。男50例、女44例,发病年龄26~85岁(中位数60岁)。原发鼻腔86例、上颌窦7例、鼻咽部1例。颈部淋巴结转移10例(7例疗前、2例疗中、1例疗后),无远处转移。采用手术±放疗方法。采用Kaplan-Meier法计算生存率并Logrank法单因素预后分析,Cox模型多因素预后分析。结果 全组1、3、5年样本数量分别为80、54、50例,1、3、5年疾病相关生存率分别为71%、33%、22%。单因素分析发现影响预后因素为年龄>55岁(P=0.034)、累及后鼻孔(P=0.011)、累及上颌窦(P=0.009)、累及硬腭(P=0.003)、颈部淋巴结转移(P=0.001)、治疗方式(P=0.038)。多因素分析发现影响预后因素为累及后鼻孔(P=0.027)、累及眼眶(P=0.005)、累及硬腭(P=0.003)。结论 鼻腔鼻窦黏膜恶性黑色素瘤的远处转移和局部复发率较高,需多学科多手段联合治疗;颈部淋巴结转移率较低;临床分期的合理性有待进一步研究。     

Conformal radiotherapy for paranasal sinus and nasal cavity tumors: three-dimensional treatment planning and preliminary results in 40 patients

PURPOSE: To assess the possibility to deliver a high and homogeneous irradiation with respect to maximal tolerated dose to the visual pathways for paranasal sinus and nasal cavity tumors. METHODS AND MATERIALS: Forty patients with advanced stage malignant tumors were treated with postoperative (30) or primary (10 patients) conformal radiotherapy (CRT). Five patients were previously irradiated. Six to 15 individually shaped isocentric noncoplanar field arrangements, using a multileaf collimator were designed. Dose-volume histograms (DVH) for the planning target volumes (PTV) and the optic pathways were analyzed in 31 cases. RESULTS: Median and maximal delivered doses to the PTV were 60 (+/-3) and 66 (+/-4) Gy. Dose distributions for critical organs are detailed. Median follow-up was 19 months (3 to 48). Local, nodal, and metastatic recurrences occurred in 8, 2, and 7 cases, respectively. Major prognostic factor for local recurrences was central nervous system (CNS) involvement. One patient died of meningitis. Two patients developed cataract, and 1 patient ipsilateral blindness due to vascular glaucoma. CONCLUSION: CRT for locally advanced paranasal sinus and nasal cavity tumors enables the delivery of high homogeneous doses to the PTV with respect to critical organs, with a low toxicity and a high local control.     

60例上皮源性鼻腔癌的临床疗效分析

目的：评价上皮源性鼻腔癌的临床疗效及影响预后的因素。方法：回顾性分析1995－1992年收治的60例上皮源性鼻腔癌。其中单纯放射治疗34例,手术＋放射治疗26例。生存统计采用Kaplan-Meier法,组间比较采用Log-rank检验,多因素分析采用Cox模型。结果：总5年生存率为55．9％,10年生存率为36．9％。早期患者（I、Ⅱ期）的5,10年生存率分别为79．0％和57．9％,晚期患者（Ⅲ、Ⅳ期）的5,10年生存率则分别为44．1％和26．0％,二者差异有显著性（P＝0.005)。手术＋放射治疗与单纯放疗的生存率差异无显著性（P＝0．33）,鳞癌的生存率明显低于腺癌（P＝0．04）,初诊时颈部有淋巴结转移者的5,10年生存率低于无颈部淋巴结转移者（P＝0.09).结论:治疗方式`颈部淋巴结转移对预后无明显影响,而病理类型`临床分期对预后有显著影响.